March 26th, 2020
Dear Valued Customers, Collaborators and Partners,
We are writing this letter to ensure you that the PhoenixBio Group continues to operate at full capacity and is committed to assisting our customers, collaborators and partners with their research needs during this extraordinary time.
We are monitoring, around the clock, the global outbreak of the coronavirus (COVID-19) and are taking all the appropriate measures to mitigate the potential impact of the unprecedented circumstances on our services and the health of our employees.
PXB-mouse/PXB-cells Production and Research Service Operations
Business and Alliance Operations
PhoenixBio continues to take all the necessary steps to prevent potential future infection of the COVID-19 virus to our employees and optimize the business operations under the current situation. We continue to operate at full capacity and are committed to assisting our customers, collaborators and partners with their research needs.
We thank you very much for your trust during this dynamic situation.
PhoenixBio Co., Ltd.
President & CEO Takashi Shimada
PhoenixBio is supporting the MAM 2020 as a Day Refreshments Sponsor and provides attendees with the refreshments on Tuesday, February 25 (Pre-Erythrocytic Biology session day).
MAM 2020 will feature leading experts in the field while providing opportunities for young researchers and scientists from malaria endemic countries to showcase their research through selected talks and posters from submitted abstracts.
The meeting is held from February 23 to February 27, 2020 at Mantra Lorne in Victoria, Australia.
PhoenixBio is pleased to announce that “Generation of Novel Chimeric Mice with Humanized Livers by Using Hemizygous cDNA-uPA/SCID Mice” is in the top 10% most cited PLOS ONE papers published in 2015.
The paper describes the humanized liver chimeric mice (PXB-mouseR) generated on PhoenixBio’s proprietary cDNA-uPA/SCID genetic background. The newly developed cDNA-uPA/SCID background allows significant improvements in the robustness and quality of the PXB-mouseR model, which has seen increased usage in a wide range of research fields, including Viral Hepatitis, Toxicity, Drug Metabolism & Pharmacokinetics, Metabolic Liver Disease, Oligonucleotide Therapeutics, and Gene Therapy.
The recognition by PLOS ONE demonstrates the utility of the PXB-mouseR across various biomedical fields and indicates the support for the model by both academic and industrial researchers. PhoenixBio is committed to contributing to the Life Sciences and will continue working with members in the Biomedical field to further their research goals.
We will be furnishing a booth at the American College of Toxicology 40th Annual Meeting & Exhibition 2019 held from November 17 to November 20, 2019 at the JW Marriott Desert Ridge in Phoenix, AZ, USA.
We will be furnishing a booth at ESGCT 27th Annual Congress 2019 held from October 22 to October 25, 2019 at Barcelona International Convention Center in Barcelona, Spain.